Svein Lien appointed ceo of Biotec Pharmacon
Lien has a financial background and extensive experience at technology and diagnostics businesses
Lien has a financial background and extensive experience at technology and diagnostics businesses, most recently as chief executive of Axis-Shield, a diagnostic company listed in London and Oslo.
Following divestment of Immunocorp Animal Health in 2008 and Immunocorp Consumer Health at the end of 2009 Biotec Pharmacon has narrowed its strategic focus to two core business areas: pharmaceutical development and marine biochemicals.
Pharmaceutical development is in the research and development phase, while Biotec Marine Biochemicals specialises in cold-adapted marine enzymes for the molecular biology and diagnostics markets.
You may also like
Manufacturing
Thermo Fisher Scientific highlights its new accelerator drug development solutions at CPHI Frankfurt 2025
The company has also announced a collaboration with OpenAI as well as a new digital toolbox, OSDPredict, which combines AI and machine learning models to predict formulation behaviour in small-molecule development